INSM vs MRNA
Insmed Incorporated and Moderna, both Healthcare
Moderna is the larger company at $25B against $21B. Over the past year MRNA returned +93% against +14% for INSM. Ryufin's sector-relative Smart Score puts MRNA ahead, 9/10 against 2/10.
| Figure | INSM | MRNA |
|---|---|---|
| Last close | $124 | $62.96 |
| Market cap | $21B | $25B |
| 1-year return | +14% | +93% |
| 5-year return | +415% | -81% |
| Ryufin Smart Scoresector-relative, 1–10 | 2/10 | 9/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Insmed Incorporated
Revenue of $425M in Q2 2026, net income null. Its largest reported line is United States, 60% of the disclosed total.
Moderna
Revenue of $145M in Q2 2026, net income null. Its largest reported line is COVID19, 81% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or read the correlation.